We investigated the expression of the cloned human c-myc gene in Xenopus laevis oocytes microinjected with different recombinants. We found that microinjected plasmid DNA carrying an intact human c-myc gene directs efficient and faithful transcription from its own two promoters. in X. laevis oocytes. This active transcription was unaffected by the presence of previously identified enhancing elements such as simian virus 72-base pair repeats or mouse immunoglobulin heavy-chain gene enhancer sequences in the construct in cis. This suggests that all necessary DNA sequences for accurate and faithful transcription recognized by the transcription machinery of the frog oocyte are self-contained. In addition, we have found that human c-myc transcripts synthesized in oocytes are properly polyadenylated at either one of two sites and also that the transcripts are spliced correctly but with low efficiency.
The structure of human and mouse c-myc genes is now known in detail (10, 15, 59, 62, 63) . The gene is encoded in three exons separated by two introns. The first exon, about 550 base pairs (bp) in length, is entirely non-coding. It contains two TATA sequences, such as commonly found at the 5' end of eucaryotic genes transcribed by RNA polymerase II (12) , and two initiation sites, separated from one another by about 165 bp. The unusually long noncoding exon sequence is tightly conserved between human and mouse genes (7, 10) , suggesting a possible role for this portion of the gene in transcriptional or translational control (38, 55) . The remaining part of the c-myc gene contains two coding exons that direct the synthesis of a protein 439 amino acids in length (63) .
Several different alterations in the c-myc locus, such as gene amplification (3, 16, 21, 40) , retroviral promoter (34, 46) and enhancer (17) insertion, and chromosomal translocation (1, 2, 19, 22, 32, 57, 59, 61) , have been discovered in tumor cells. Activation of the c-myc genes involved in such drastic changes has been reported in most of these tumors. The importance of temporal regulation during the cell cycle and cell differentiation has been also reported (14, 36) . Study of the cell cycle dependency of c-myc gene expression in fibroblasts and lymphocytes has indicated that c-myc is an inducible gene regulated by specific growth signals and also that the expression starts and peaks in the early G1 phase of the cell cycle (14, 36) . The effect of in vitro-induced cell differentiation on c-myc expression has also been investigated. During the differentiation of teratocarcinoma stem cells to endoderm cells (14) , c-myc gene expression is diminished markedly. Thus, a relaxation of normal regulation of the cell cycle-dependent and cell differentiation-restricted expression of c-myc may be sufficient for partial loss of growth control. In Burkitt lymphoma cells, transcription of the normal, untranslocated c-myc allele remains inactive, whereas the translocated and rearranged c-myc is constitutively expressed at a high level (4, 10, 33, 48) . Similar observations have been reported for mouse plasmacytomas (2, 59) . These results have suggested that the normal c-myc gene may be either autorepressed directly or indirectly by c-myc gene products derived from the rearranged allele (38) * Corresponding author.
or suppressed by a differentiation-specific mechanism from which the altered c-myc gene escapes (47, 48) .
To acquire some insights into the control mechanism of c-myc gene expression, we have studied the expression of c-myc genes in Xenopus laevis oocytes microinjected with various human c-myc gene recombinants. Protein-coding genes, such as the simian virus 40 (SV40) early and late gene (64) , the herpesvirus thymidine kinase gene (44) , and the sea urchin histone gene (23, 52) , transcribed by RNA polymerase II have been shown to be expressed efficiently. However, some of the cell type-specific genes such as rabbit ,-globin (54) and the chicken ovalbumin gene (65) have been shown to generate only inaccurate transcripts initiating from the plasmid parts, suggesting selectivity of this system in faithful expression of the foreign genes microinjected (30) . Here we show that the cloned intact human c-myc gene is transcribed very efficiently and accurately from its own promotors in X. laevis oocytes after microinjection. This active transcription does not require any modifications of the gene such as fusion of the virus promotor or enhancing sequences. The transcripts are properly polyadenylated, and some of them are correctly spliced.
MATERIALS AND METHODS
Plasmid constructions. pLcMycHE was constructed by excising the HindIIIIEcoRI 8.2-kilobase (kb) fragment carrying the human genomic c-myc sequences from the original X clone, XMC41 (20) , and inserting it at the HindIII and EcoRI sites of pML2 (41), a derivative of pBR322. pSV2cMycHE was constructed as follows. First, we excised the HindIIIIEcoRI 8.2-kb DNA fragment from plasmid pLcMycHE. Then this DNA fragment was inserted into the HindIII and EcoRI sites of the pSV2CAT (26) vector after removing the CAT gene and a part of the SV40 sequences from this vector. pHEa5'myc and pHEs5'myc recombinants were constructed as follows. The mouse immunoglobulin H (IgH) enhancer sequence previously identified between J and C,u genes (6, 25) (41) , resulting in the pLcMycHE clone. The location of the genomic fragment used for subcloning is indicated.
for the insert and its orientation to the c-myc gene. In the pHEa5'myc recombinant, the orientation of the immunoglobulin enhancer is opposite the c-myc gene, whereas it orients in the same direction as c-myc in the pHEs5'myc recombinant. XMC41 and pJ3J4 were obtained from C. M. Croce. pSV2CAT was a generous gift from B. H. Howard.
Oocyte i jection and RNA preparation. Typically, a set of 20 oocytes was injected for each sample as described by Gurdon (29) . Oocytes were homogenized in proteinase K solution, and total RNAs were extracted with phenol-chloroform and then precipitated with ethanol as described previously (49) . The RNAs were further purified by an oligodeoxythymidylate selection procedure (5).
Si nuclease mapping. RNA was analyzed by the Si nuclease mapping procedure (9) . End-labeling was performed by the method of Maxam and Gilbert (43) , using polynucleotide kinase (5' end) or Escherichia coli DNA polymerase I Klenow fragment (3' end). The uniformly labeled DNA probe was prepared according to Ley et al. (39) . Typically, the polyadenylated [poly(A)+] RNAs from the equivalent of one oocyte or 20 ,ug of cytoplasmic RNAs from tissue-cultured cells were used for each assay. The 32P-labeled DNA probes were heat denatured, hybridized in 80%o formamide to poly(A)+ or cytoplasmic RNAs at 56.5°C for 10 h, digested with 80 U of nuclease S1, and analyzed by electrophoresis on a 7 M urea-4% polyacrylamide gel (42) .
RESULTS
Construction of human c-myc recombinants. In this study, various human c-myc gene recombinants were constructed to test gene expression in the X. laevis oocyte system. The structure of the human c-myc gene is shown in Fig. 1 . In some of the recombinants, sequences from the SV40 genome or mouse IgH gene are also added to the c-myc gene. All c-myc gene recombinants used in this study are summarized in Table 1 and are schematically presented in Fig. 2 .
Human c-myc genes are transcribed from their own two microinjected the human genomic c-myc recombinant pLcMycHE ( Fig. 2A ) DNAs into X. laevis oocytes. After 24 h, the poly(A)+ RNA was prepared from the oocytes and analyzed for the presence of c-myc transcripts by the S1 mapping procedure (9) . The c-myc gene contains two TATA sequences and two initiation sites separated by 165 bp at the 5' side of the first noncoding exon (7, 62) . We first determined whether any of the human c-myc-specific transcripts initiated from their two cap sites were synthesized in oocytes. Two S1 nuclease-resistant DNA fragments, 515 and 350 nucleotides in length, were detected in the oocytes microinjected with pLcMycHE ( Fig. 3A , lane 4). As we have previously shown (4, 62) , these two lengths correspond to the distance from the 3' PvuII site to the two initiation sites of the c-myc gene (Fig. 3B ). As controls (Fig. 3A , lanes 2 and 3), we used the RNAs prepared from Burkitt lymphoma BL2 (19) and also from promyelocytic leukemia cell line HL60 (21) . It has been shown that these cells synthesize elevated levels of c-myc mRNAs (about 50 copies per cell; see reference 10) and also that two c-myc promotors are utilized to a different extent in these cells (62) . Our results clearly indicate that the two promotor and initiation sites of the human c-myc genes are accurately recognized and utilized for c-myc RNA synthesis in the Xenopus oocytes.
Since coinjection of a-amanitin at 5 pg per oocyte with the recombinant abolished the S1 nuclease-resistant DNA products of 515 and 350 nucleotides in length (data not shown), we concluded that the c-myc-specific RNAs initiating from the two sites were transcribed by RNA polymerase 11 (31) . Various enhancer sequences have no effect on c-myc transcription from its own two promotors in Xenopus oocytes. We also microinjected pSV2cMycHE, pHEaS'myc, or pHEs5'myc clone DNAs, which contain the replication origin of the SV40, with the enhancer or the mouse IgH enhancer, in addition to human c-myc genes ( Fig. 2A and B) . The total level of the c-myc gene transcription from pSV2cMycHE DNAs (Fig. 3A, lane 5 Fig. 3A, lane 3) . We estimate that each oocyte microinjected with the cloned c-myc genes (1 ng or 5 x 107 copies of the templates) synthesizes 2.5 x 108 copies of the c-myc RNAs, equivalent to the amount of c-myc mRNAs synthesized by 5 x 10 6 BL2 or HL60 cells. From these results on S1 mapping analysis of the human c-myc transcripts, we conclude that, without additional cis-acting elements, the 5'-flanking sequence region of the human c-myc gene containing the two TATA sequences can direct accurate and active transcription of c-myc RNA in the Xenopus oocyte after microinjection. Fig. 4B . Although the human c-myc gene contains two potential poly(A) addition sites separated by 165 bp in the 3'-flanking region (7) , the second site (site 2, indicated in Fig. 4B ) is dominantly utilized for c-myc mRNA synthesis in various Burkitt lymphoma and human lymphoblastoid cells (4) . The two poly(A) addition sites were utilized equally for the formation of 3' ends of the c-myc RNAs transcribed from pLcMycHE (lane 5) and pSV2cMycHE (lane 6) recombinants (Fig. 4A) , whereas the RNAs synthesized in three Burkitt lymphoma cells have their 3' ends predominantly at the second sites as expected. Since RNAs prepared from oocytes were selected for the poly(A)+ fraction by the oligodeoxythymidylate column three times, the 3' ends of the c-myc RNAs, detected by Si mapping analysis, are most likely polyadenylated at these sites. Therefore, we conclude that in oocytes the injected c-myc genes direct the synthesis of poly(A)+ c-myc RNAs whose 3' ends are at one of the two poly(A) addition sites.
Splicing of the human c-myc gene transcripts also occurs in Xenopus oocytes. Splicing of the c-myc gene transcripts was also analyzed. First, we assayed for RNA splicing between the second and third exons of the c-myc gene transcripts, using a 5'-end-labeled human c-myc cDNA probe (Fig. SB) . The correctly spliced c-myc RNA produced in oocytes protected a full-length DNA probe (1, 034 nucleotides) from S1 nuclease digestion (lanes 5 and 6) corresponding to the distance between the BclI site in the 3' untranslated region and the 5' end of the c-myc cDNA insert of the pRyc7.4 probe (48). These S1 nuclease-resistant DNA products were observed in control lanes for the c-myc RNAs prepared from various Burkitt lymphomas (lanes 2 to 4). The unspliced precursor type c-myc RNAs protected a 637-nucleotide fragment of this cDNA probe, corresponding to the distance between the BcII site and the 5' end of the third exon (Fig.  5B) . It has been previously reported that Xenopus oocytes can correctly but inefficiently splice microinjected precursor RNAs (27) or the transcripts synthesized from injected DNAs (64) . Our results on analysis of splicing between E2 and E3 exons of c-myc gene transcripts also indicate that the oocytes accurately splice the human c-myc transcripts but with low efficiency. By comparing the two S1 nuclease-resistant DNA products of 1,034 and 637 nucleotides, we estimate that up to 30% of the c-myc transcripts were properly spliced. These results were also confirmed for splicing between El and E2 exons of the c-myc transcripts produced in Xenopus oocytes by using another cDNA clone spanning the two exons (data not shown).
DISCUSSION
Expression of human c-myc gene in Xenopus oocytes. Although accurate and efficient transcription initiation of microinjected 5S rRNA (13) and tRNA (18, 37) The cellular oncogene c-myc is believed to play important roles in regulation of the growth and development of normal cells, as do other c-oncogenes (11, 35) (8, 24, 28) increase accurate and efficient transcription initiation of the c-myc gene in Xenopus oocytes. In other words, the intact human c-myc gene fragment inserted into the pLcMycHE recombinant ( Fig. 1 and 2A) is self-sufficient with respect to all signal sequences necessary for active transcription from the correct initiation sites. This result was unexpected, since there is a commonly accepted impression that in various tumors the c-myc gene is activated only by drastic alterations of the c-myc locus such as retroviral promotor insertion, retrovirus enhancer insertion, gene amplification, or chromosomal translocation. Accumulated evidence has sugman c-myc RNAs gested the existence of a delicately balanced control mechc-myc gene plasanism which operates on normal c-myc genes in a cell microinjected oodifferentiation-specific manner (48) or in a cell cycle-depenanalysis (9). The ired, hybridized in 56.5°C for 10 h, phoresis on a 7 M )usly (50 (30, 44, 64) . Thus, one is led to wonder if the low level of c-myc expression in normal cells is due to the effects of some repressor-like control factor which suppresses or turns off (in some cases) c-myc transcription. Such a negative control may be consistent with the difference between the rapid transcription of cloned c-myc genes microinjected and a low level of transcription of normal cellular c-myc genes. In the former, the number of genes microinjected into oocytes (1 ng or 5 x 107 copies per oocyte) may be far in excess of the physiological concentration of the putative factor, whereas in the latter a single copy of the c-myc gene may be tightly regulated by such a regulatory molecule. Alternatively, the level of c-myc transcription in injected oocytes may indicate the release of the genes from regulatory factors present in somatic cells but absent in these undifferentiated germ cells, oocytes.
3'-End formation, polyadenylation, and splicing of c-myc gene transcripts in Xenopus oocytes. In this study, we have demonstrated that not only accurate and efficient transcription but also some post-transcriptional processing of c-myc transcripts take place in Xenopus oocytes microinjected with cloned human c-myc genes. It has been shown previously that Xenopus oocytes are able to carry out some of the post-transcriptional steps required for modifications of mRNA precursors synthesized by polymerase II from injected genes (64) . In this study transcripts. of c-myc genes were found to have been properly polyadenylated at either one of the previously identified two poly(A) addition sites (4, 7) . The utilization ratio of the two sites for 3'-end formation was quite different in oocytes and in various Burkitt lymphoma cells. Namely, the promotor-distal site (site 2 in Fig.  4B ) was favored over the proximal site (site 1 in Fig. 4B We have also shown that accurate splicing of the c-myc transcripts synthesized from the injected genes occurs in Xenopus oocytes. Although the efficiency of splicing is not necessarily high, the inefficiency of this RNA processing step in Xenopus oocytes has been reported for several other gene transcripts (27, 64) . Regardless of efficiency, our results demonstrate that the c-myc RNAs transcribed from their own promotors are polyadenylated at one of two potential 3'-end sites, that some of them are spliced correctly, and that they give rise to a significant amount of mature functional human c-myc mRNAs. It will be interesting to know whether any of these c-myc mRNAs are translated into functional c-myc proteins in Xenopus oocytes. The possibility is presently being investigated.
